N/A N=42 A Pilot Study to Evaluate the Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Obstructive Sleep Apnea
Sleep Apnea, Obstructive · Down Syndrome
Primary: Serious Adverse Events — 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 Zinc Supplementation and Cardiovascular Risk in HIV
HIV · Inflammation
Primary: Percentage of Participants With Decreased Inflammation Markers sCD14, sTNF-RI, and High Sensitivity C Reactive Protein (Hs-CRP) — 15; 15; 14; 15 Participants
Phase 1 N=271 Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants
Virus, Zika · Zika Virus Disease · Flavivirus Infections
Primary: Percentage of Participants With Solicited Local Injection Site Reactions by Severity Within 7 Days After Dose 1 of PIZV or Placebo — 13.3; 30.0; 32.3; 38.7 percentage of…
Phase 2 N=4 Benzodiazepine Discontinuation in Opioid Agonist Therapy
Substance Use Disorders
Primary: Participant Acceptability of the Interventions — 1; 0 Participants
N/A N=48 Performance Evaluation of Two Daily Disposable Toric Lens Designs in Habitual Soft Contact Lens Wearers
Astigmatism
Primary: Overall Ease of Lens Handling — 9.0; 8.8 units on a scale
N/A N=1,824 Transfusion of Prematures Trial
Infant, Newborn, Diseases · Infant, Extremely Low Birth Weight · Infant, Small for Gestational Age
Primary: Death or Neurodevelopmental Impairment — 423; 422; 422; 425 Participants — p=0.93
N/A N=75 Social Media-Based Parenting Program for Women With Postpartum Depressive Symptoms
Postpartum Depression · Parenting · Parent-Child Relations
Primary: The Parent Child Early Relational Assessment (PCERA) — 3.0; 3.2; 3.3; 3.3 score on a scale
Phase 4 N=1,003 Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation
Dystocia
Primary: Number of Participants Delivered by Cesarean — 73; 72 Participants
N/A N=149 Social Media Intervention for Cannabis Use in Emerging Adults
Cannabis Use
Primary: Frequency of Cannabis Use as Reported on the Timeline Follow-Back (TLFB) — 18.0; 14.9 days — p=.980
Phase 2 N=122 Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
Adenocarcinoma of the Lung · Extensive Stage Small Cell Lung Cancer · Limited Stage Small Cell Lung Cancer
Primary: Biomarker FGFR1 (ISH/SISH) Score (Part A) — 0.93; 0.07; 0.579; 0.42 gene copy number
Phase 2 N=11 Gene Therapy for Achromatopsia (CNGA3)
Achromatopsia
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…
N/A N=37 Cognitive Adaptations to Reduce Emotional Stress Associated With Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Problem Areas in Diabetes Survey - Parent Revised (PAID-PR) — 32.65; 39.69 units on a scale
N/A N=20 Virtual Reality (VR) to Improve Quality of Life in Patients Diagnosed With Neurological Disorders
Multiple Sclerosis · Chronic Pain · Neurological Disorder
Primary: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Pain Intensity - Short Form 3a Score — 0.42 score on a scale
Phase 2 N=145 Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia
Chronic Kidney Disease · Anemia
Primary: Number (%) of Participants With an Hb Response by Week 17 — 19; 24; 21; 23 Participants
Phase 2 N=6 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Anaplastic Thyroid Cancer
Primary: Overall Response (OR) — 0; 3; 3; 1 Participants